Dadoo Rajeev 4
4 · ARS Pharmaceuticals, Inc. · Filed Jun 26, 2026
Research Summary
AI-generated summary of this filing
ARS Pharmaceuticals (SPRY) Director Rajeev Receives 30,000-Share Award
What Happened
Dadoo Rajeev, a director of ARS Pharmaceuticals, was granted a derivative equity award covering 30,000 shares on June 24, 2026. The Form 4 reports the acquisition price as $0.00 (code A — award/grant), indicating an equity award rather than an open-market purchase or sale. The filing does not report a cash value or strike price for the award.
Key Details
- Transaction date: 2026-06-24; Form 4 filed: 2026-06-26 (timely within the Section 16 filing window).
- Instrument: Derivative award (reported as "A"); 30,000 shares acquired at $0.00.
- Vesting: The award vests in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting of stockholders (per footnote).
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Filing timeliness: Reported promptly (not marked late).
Context
This was a grant of a future equity interest (likely an option or restricted award) that vests over time rather than an immediate stock purchase. Such awards are typically part of director compensation and do not necessarily signal immediate buying or selling intent. Because no exercise price or immediate sale was reported, there was no cash exchanged or realized gain at the time of the grant.
Insider Transaction Report
- Award
Stock Option (right to buy)
[F1]2026-06-24+30,000→ 30,000 totalExercise: $10.54Exp: 2036-06-23→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.